Oneness Biotech Co., Ltd. (TPEX:4743)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
50.40
+0.70 (1.41%)
May 29, 2026, 1:30 PM CST
Market Cap24.15B -13.5%
Revenue (ttm)140.52M +19.8%
Net Income-1.03B
EPS-2.16
Shares Out 479.21M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,199,474
Open50.40
Previous Close49.70
Day's Range50.00 - 50.90
52-Week Range49.00 - 82.70
Beta0.79
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rhe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 4743
Full Company Profile

Financial Performance

In 2025, Oneness Biotech's revenue was 129.12 million, an increase of 9.49% compared to the previous year's 117.93 million. Losses were -1.04 billion, -10.33% less than in 2024.

Financial Statements